Novo Nordisk A/S (0QIU.L)
| Chiusura precedente | N/D |
| Rendimento dall'inizio dell'anno (YTD) | N/D |
| Coefficiente di spesa (netto) | N/D |
| Categoria | N/D |
| Ultimo guadagno in conto di capitale | N/D |
| Rating di MorningStar | N/D |
| Rating di Morningstar (rischio) | N/D |
| Rating di sostenibilità |
| Attività nette | N/D |
| Beta (5 anni mensile) | N/D |
| Rendimento | N/D |
| Rendimento medio 5a | N/D |
| Turnover portafoglio titoli | N/D |
| Ultimo dividendo | N/D |
| Media per la categoria | N/D |
| Data di inizio disponibilità | N/D |
- GlobeNewswire
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 20 March 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme i
- GlobeNewswire
Novo Nordisk announces changes in Executive Management
Bagsværd, Denmark, 7 March 2023 – Novo Nordisk today announced the following changes in Executive Management. Monique Carter, executive vice president (EVP), Global People & Organisation, has decided to leave Novo Nordisk to pursue an external opportunity, allowing her to be closer to her family in the UK. Monique Carter joined Novo Nordisk in 2018 as senior vice president (SVP) for People & Organisation, and in 2019 she was promoted to EVP, Global People & Organisation. Tania Sabroe is promoted
- GlobeNewswire
Novo Nordisk to expand R&D presence in greater Boston area
Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development activities. Novo Nordisk anticipates adding more than 200 new jobs in the Boston area
